A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice

Exposure to high doses of ionizing radiation can result in hematopoietic acute radiation syndrome (H-ARS) and delayed effects of acute radiation exposure (DEARE). There is no radiation medical countermeasure (MCM) approved by the U.S. Food and Drug Administration which can be used prior to radiation...

Full description

Saved in:
Bibliographic Details
Published in:International journal of radiation biology 2022-05, Vol.98 (5), p.958-967
Main Authors: Singh, Vijay K., Fatanmi, Oluseyi O., Wise, Stephen Y., Carpenter, Alana, Nakamura-Peek, Sara, Serebrenik, Artur A., Kaytor, Michael D.
Format: Article
Language:English
Subjects:
Acute Radiation Syndrome - prevention & control
Animal model
Animals
BIO 300
Dose-Response Relationship, Radiation
Female
Hematopoietic System
Male
Mice
prophylactic
radiation
Radiation, Ionizing
Radiation-Protective Agents - pharmacology
radioprotection
Whole-Body Irradiation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Exposure to high doses of ionizing radiation can result in hematopoietic acute radiation syndrome (H-ARS) and delayed effects of acute radiation exposure (DEARE). There is no radiation medical countermeasure (MCM) approved by the U.S. Food and Drug Administration which can be used prior to radiation exposure to protect exposed individuals. Different formulations containing synthetic genistein (BIO 300) are being developed to counter the harmful effects of radiation exposure. We investigated the efficacy of a BIO 300 oral powder (OP) formulation as a prophylactic radiation MCM against a lethal dose of cobalt-60 gamma-radiation in CD2F1 male mice while comparing to other formulations of BIO 300 and Neulasta (PEGylated filgrastim), a standard of care drug for H-ARS. BIO 300 OP provided significant radioprotection against ionizing radiation in mice when administered twice per day for six days prior to total-body radiation exposure. Its radioprotective efficacy in the murine model was comparable to the efficacy of a single subcutaneous (sc) injection of Neulasta administered after total-body radiation exposure. Our results demonstrate that BIO 300 OP, which can be administered orally, is a promising prophylactic radiation countermeasure for H-ARS.
ISSN:0955-3002
1362-3095
DOI:10.1080/09553002.2021.1981556